Poxvirus-based active immunotherapy synergizes with CTLA-4 blockade to increase survival in a murine tumor model by improving the magnitude and quality of cytotoxic T cells

The dramatic clinical benefit of immune checkpoint blockade for a fraction of cancer patients suggests the potential for further clinical benefit in a broader cancer patient population by combining immune checkpoint inhibitors with active immunotherapies. The anti-tumor efficacy of MVA-BN-HER2 poxvi...

Descripción completa

Detalles Bibliográficos
Autores principales: Foy, Susan P., Mandl, Stefanie J., dela Cruz, Tracy, Cote, Joseph J., Gordon, Evan J., Trent, Erica, Delcayre, Alain, Breitmeyer, James, Franzusoff, Alex, Rountree, Ryan B.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2016
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4840227/
https://www.ncbi.nlm.nih.gov/pubmed/26961085
http://dx.doi.org/10.1007/s00262-016-1816-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4840227/
https://www.ncbi.nlm.nih.gov/pubmed/26961085
http://dx.doi.org/10.1007/s00262-016-1816-7

Ejemplares similares